The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

By N. Müller, M. Schwarz, S. Dehning, A. Douhe, A. Cerovecki, B. Goldstein-Müller, I. Spellmann, G. Hetzel, K. Maino, N. Kleindienst and 3 more. Molecular Psychiatry, 2006

792 citations recorded by the source corpus.

Subfields: Behavioral Neuroscience, Biological Psychiatry, Pharmacology

View Paper: https://www.semanticscholar.org/paper/612ebc118cff9848d263e6cc0d8f63254c60db74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Behavioral Neuroscience

In Biological Psychiatry

In Pharmacology

Citations in the corpus

Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior (2012, result): “Nevertheless, both studies involved small sample sizes, and in the celecoxib study, 50% or more of the sample in each group dropped out before conclusion of the study (Muller et al, 2006).”
Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. (2007, background): “Interestingly, although neuroendocrine parameters were not assessed, COX-2 inhibitors were recently found to augment the effects of the antidepressant, reboxetine, in treating patients with major depression (Muller et al., 2006).”
Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018, background): “In line with that, treatment with anti-inflammatory agents has the potential to reduce depressive symptoms (110).”
From Stress to Inflammation and Major Depressive Disorder: A Social Signal Transduction Theory of Depression (2014, methodology): “Moreover, 75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo (Müller et al., 2006; see also Akhondzadeh et al., 2009).”
Inflammation-Associated Depression: From Serotonin to Kynurenine (2010, background): “Blockade of the inducible cyclooxygenase-2 enzyme that mediates the synthesis of prostaglandins of the E2 series in response to cytokines enhanced the antidepressant effect of the specific norepinephrine re-uptake inhibitor reboxetine, although the dropout rate was particularly elevated in this stud”
Immune System to Brain Signaling: Neuropsychopharmacological Implications (2011, background): “In addition, in medically healthy patients with major depression, the COX-2 inhibitor, celecoxib, was shown to significantly enhance antidepressant efficacy of the norepinephrine reuptake inhibitor, reboxetine, in a small double blind placebo-controlled trial (Muller et al., 2006).”
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression (2009, background): “The clinical efficacy of antidepressant treatments may be enhanced by concurrent administration of agents with anti-inflammatory effects, such as celecoxib, a cyclooxygenase-2 inhibitor (Muller et al. 2006).”
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis (2011, positive): “…depressive symptoms in humans (Reichenberg et al, 2001; Wright et al, 2005; Capuron et al, 2009; Eisenberger et al, 2009; DellaGioia and Hannestad, 2010), and studies showing that anti-inflammatory and anti-TNFa drugs can ameliorate depressive symptoms (Muller et al, 2006; Tyring et al, 2006).”
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression (2009, positive): “Similarly, medically healthy depressed patients who received the selective cyclooxygenase-2 inhibitor, celecoxib, in combination with reboxetine showed greater symptomatic improvement versus patients randomized to reboxetine plus placebo (19).”
Inflammation and clinical response to treatment in depression: A meta-analysis. (2015, neutral): “Additionally, non-steroidal anti-inflammatory drugs might be beneficial as adjunctive treatments in unipolar (Akhondzadeh et al., 2009; Muller et al., 2006) and bipolar (Nery et al., 2008) disorders and the TNFα antagonist infliximab may particularly benefit depressed individuals with a history of…”
Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels (2019, background): “Anti-inflammatory treatment has antidepressant effects (Müller et al., 2006; Köhler et al., 2014; Kappelmann et al., 2018).”